Last reviewed · How we verify
CAIVT
CAIVT is a live attenuated influenza vaccine designed to provide broad protection against multiple influenza virus strains through intranasal delivery.
CAIVT is a live attenuated influenza vaccine designed to provide broad protection against multiple influenza virus strains through intranasal delivery. Used for Influenza prevention in pediatric and adult populations.
At a glance
| Generic name | CAIVT |
|---|---|
| Sponsor | MedImmune LLC |
| Drug class | Live attenuated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
CAIVT (Cold-Adapted Influenza Vaccine Trivalent) is a live attenuated influenza vaccine that uses temperature-sensitive, cold-adapted virus strains that replicate efficiently in the cooler upper respiratory tract but are attenuated in the warmer lower respiratory tract and systemic tissues. This approach stimulates both mucosal and systemic immune responses, providing protection against influenza infection while minimizing systemic reactogenicity.
Approved indications
- Influenza prevention in pediatric and adult populations
Common side effects
- Nasal congestion
- Runny nose
- Sore throat
- Cough
- Fever
Key clinical trials
- Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children (PHASE2)
- Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine. (PHASE2)
- Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |